{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Volumetric measurements of the primary tumor using an elliptical model (0.5 x the product of the 3 largest perpendicular diameters) to assess response to neoadjuvant therapy. The RECIST (Response Evaluation Criteria in Solid Tumors) from the NCI will be used for assessment of the size of measurable metastases, including nodal metastases. Primary Tumor Measurement: Technical guidelines for cross-sectional imaging computed tomography (CT) slice thickness should be 5mm or less and the diameter of the \"measurable\" mass should be at least twice the reconstructed slice thickness. Smaller masses are considered detectable, but will be counted as \"non-measurable.\" Complete Response (CR): Complete disappearance of the tumor confirmed at \\>4 weeks. Partial Response (PR): At least 64% decrease in volume compared to the measurement obtained at study enrollment. Progressive Disease (PD): At least 40% increase in tumor volume compared to the smallest volume obtained since the beginning.","groups":[{"description":"Parameningeal (without intracranial extension) and paraspinal tumors receive chemotherapy starting Week 1 and begin radiation therapy at Week 20. Weeks 1-6: vincristine sulfate and irinotecan hydrochloride. Weeks 7-34: vincristine sulfate and irinotecan hydrochloride, Cyclophosphamide with MESNA, Doxorubicin hydrochloride, Etoposide, Ifosfamide with MESNA. Weeks 35-54: vincristine sulfate, Dactinomycin, irinotecan hydrochloride and Cyclophosphamide with MESNA and Filgrastim. Radiation therapy beginning at Week 20. Second look conventional surgery: Surgical resection other than biopsy will be applicable for the majority of patients","id":"OG000","title":"High_Risk_Rhabdomyosarcoma"}],"paramType":"NUMBER","populationDescription":"All eligible patients with protocol week tumor assessment (N=102)","reportingStatus":"POSTED","timeFrame":"Protocol week 6 evaluation","title":"Number of Patients With Complete or Partial Response Assessed by RECIST Criteria","type":"PRIMARY","unitOfMeasure":"percentage of participants"}